Adlai Nortye Group Ltd. (ANL)
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Adlai Nortye Ltd.
No splits on record
Nothing in ANL's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $5M | $0 | $0 | $0 | $45.73M | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $1.51M | $1.48M |
| Gross Profit | $5M | $0 | $0 | $0 | $45.73M | -$1.51M | -$1.48M |
| Gross Margin | 100.0% | - | - | - | 100.0% | - | - |
| Research and Development | $32.83M | $44.91M | $58.15M | $54.49M | $42.1M | $19.04M | $13.34M |
| Selling, General, and Administrative | $7.79M | $9.44M | $14.82M | $12.43M | $12.45M | $5.56M | $4.3M |
| Other | $80K | -$1.43M | -$425K | $350K | -$183K | $0 | $0 |
| Total Operating Expenses | $40.7M | $52.93M | $72.55M | $67.27M | $54.37M | $24.59M | $17.64M |
| Operating Income (EBIT) | -$35.7M | -$52.93M | -$72.55M | -$67.27M | -$8.65M | -$26.1M | -$19.12M |
| Operating Margin | -714.0% | - | - | - | -18.9% | - | - |
| Interest Expense | $1.49M | $1.94M | $791K | $433K | $1.34M | $1.75M | $466K |
| Interest Income | $0 | $0 | $62K | $550K | $32K | $24K | $23K |
| Other Income (Expense) | $170K | $1.06M | -$36.68M | $8.48M | -$48.03M | -$37.28M | $1.29M |
| Income Before Tax (EBT) | -$35.53M | -$51.87M | -$109.23M | -$58.79M | -$56.68M | -$63.38M | -$17.83M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$35.53M | -$51.87M | -$109.23M | -$58.79M | -$56.68M | -$63.38M | -$17.83M |
| Net Income Margin | -710.6% | - | - | - | -124.0% | - | - |
| Supplementary Data | |||||||
| EPS | -3.33 | -4.89 | -15.42 | -4.77 | -4.62 | -7.62 | -2.10 |
| Diluted EPS | -3.33 | -4.89 | -15.42 | -4.77 | -4.62 | -7.62 | -2.10 |
| Weighted Average OS | 10.66M | 10.64M | 6.80M | 12.30M | 12.30M | 8.48M | 8.48M |
| EBITDA | -$32.63M | -$48.05M | -$106.24M | -$56.32M | -$53.51M | -$59.97M | -$15.88M |
| EBITDA Margin | -652.5% | - | - | - | -117.0% | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $23.79M | $60.9M | $91.49M | $42.76M | $64.13M | $24.21M | $6.02M |
| Short-Term Investments | $0 | $7K | $7.01M | $21.29M | $53.81M | $241K | $0 |
| Cash and Short-Term Investments | $23.79M | $60.91M | $98.5M | $64.05M | $117.94M | $24.5M | $6.02M |
| Accounts Receivable | $1.39M | $1.17M | $359K | $346K | $1.93M | $394K | $92K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 | $0 | $0 | $2.82M | $324K |
| Total Current Assets | $26.89M | $64.06M | $101.19M | $66.3M | $124.54M | $28.59M | $6.43M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $3.02M | $2.71M | $3.8M | $5.88M | $6.59M | $6.59M | $3.34M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $19K | $40K | $63K | $89K | $97K | $11K | $115K |
| Long-Term Investments | $4.25M | $4.16M | $24.85M | $0 | $0 | $0 | $81K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $71K | $0 |
| Other Long-Term Assets | $253K | $304K | $282K | $327K | $455K | $1.48M | $832K |
| Total Long-Term Assets | $7.54M | $7.21M | $28.99M | $6.29M | $7.14M | $8.15M | $4.37M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $34.43M | $71.27M | $130.19M | $72.59M | $131.69M | $36.74M | $10.8M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $12.64M | $10.15M | $14.35M | $13.1M | $2.98M | $1.53M | $5.26M |
| Short-Term Debt | $25.25M | $26.33M | $30.36M | $4.31M | $10.46M | $9.08M | $10.92M |
| Current Income Tax Payable | $0 | $75K | $130K | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $5M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $597K | -$3.06M | $0 | $290.37M | $0 | $77.38M | $4.14M |
| Total Current Liabilities | $41.63M | $45.36M | $49.67M | $312.65M | $17.5M | $87.99M | $20.32M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $634K |
| Long-Term Unearned Revenue | $0 | $0 | $5M | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $297.56M | $78.41M | $58.83M |
| Total Long-Term Liabilities | $1.13M | $425K | $5.47M | $1.24M | $299.62M | $80.31M | $59.86M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $42.76M | $45.78M | $55.14M | $313.89M | $317.11M | $168.3M | $80.18M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $10.98M | $10.98M | $10.98M | $0 |
| Common Stock | $12K | $11K | $11K | $4K | $4K | $3K | $2K |
| Retained Earnings | -$464.85M | -$429.32M | -$377.45M | -$268.22M | -$209.43M | -$159.15M | -$86.62M |
| Comprehensive Income & Other | $17.25M | -$4.54M | -$4.24M | -$4.16M | -$1M | $27.59M | $17.24M |
| Other Stockholders' Equity | $456.51M | $454.79M | $452.48M | $26.92M | $24M | $27.59M | $17.24M |
| Total Equity | -$8.32M | $25.48M | $75.05M | -$241.29M | -$185.43M | -$131.56M | -$69.38M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $34.43M | $71.27M | $130.19M | $72.59M | $131.69M | $36.74M | $10.8M |
| Supplementary Data | |||||||
| Total Debt | $26.38M | $27.23M | $31.55M | $6.54M | $13.35M | $10.98M | $11.95M |
| Net Debt | $2.59M | -$33.68M | -$59.94M | -$36.21M | -$50.79M | -$13.22M | $5.93M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$35.62M | -$51.87M | -$104.87M | -$58.79M | -$56.68M | -$63.38M | -$17.83M |
| Depreciation & Amortization | $1.41M | $1.87M | $2.2M | $2.04M | $1.83M | $1.51M | $1.48M |
| Deferred Income Tax | $0 | $0 | $0 | -$1.04M | -$67K | $0 | $0 |
| Stock-Based Compensation | $0 | $2.45M | $4.33M | $6.08M | $3.39M | $2.27M | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $2.5M | -$4.2M | $1.25M | $10.12M | $600K | -$3.86M | $482K |
| Other Working Capital | -$4.79M | -$1.34M | $4.87M | $5.13M | -$350K | -$7.44M | $2.54M |
| Total Working Capital Change | -$2.29M | -$5.54M | $6.12M | $15.25M | $250K | -$11.31M | $3.02M |
| Other Non-Cash Items | $2.96M | $1.27M | $35.57M | -$6.76M | $48.25M | $36.31M | -$1.59M |
| Net Cash from Operating | -$33.54M | -$51.82M | -$56.65M | -$43.22M | -$3.03M | -$34.59M | -$14.92M |
| Investing Activities | |||||||
| Capital Expenditures | -$187K | -$170K | -$200K | -$1.27M | -$1.12M | -$1.62M | -$185K |
| Acquisitions | $0 | -$4.21M | $0 | -$2K | -$102K | $10K | $434 |
| Purchases of Investments | -$20.49M | -$60.55M | -$31.83M | -$58.98M | -$81.23M | -$28.52M | $0 |
| Sales of Investments | $5.05M | $92.26M | $21.02M | $88.06M | $27.46M | $28.52M | $0 |
| Other Investing Activities | $0 | $734K | $54K | $569K | $134K | $0 | $0 |
| Net Cash from Investing | -$15.62M | $28.07M | -$10.95M | $28.38M | -$54.86M | -$1.61M | -$185K |
| Financing Activities | |||||||
| Debt Repaid | - | $1.02M | $1.1M | $1.07M | $966K | - | - |
| Common Stock Issuance | $0 | $152K | $91.78M | $0 | $97.37M | -$1.23M | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.81M | -$1.87M | -$602K | -$292K | -$1.19M | $57.7M | $16.22M |
| Net Cash from Financing | -$3.82M | -$6.58M | $116.24M | -$6.78M | $97.2M | $53.89M | $16.22M |
| Forex Effect | $15.87M | -$257K | $100K | $254K | $561K | $504K | $0 |
| Net Change in Cash | -$37.12M | -$30.59M | $48.73M | -$21.37M | $39.87M | $18.19M | $1.11M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$33.54M | -$51.82M | -$56.65M | -$43.22M | -$3.03M | -$34.59M | -$14.92M |
| Capital Expenditure | -$187K | -$170K | -$200K | -$1.27M | -$1.12M | -$1.62M | -$185K |
| Free Cash Flow | -$33.73M | -$51.99M | -$56.85M | -$44.49M | -$4.15M | -$36.22M | -$15.11M |
| Cash at Beginning | $60.9M | $91.49M | $42.76M | $64.13M | $24.26M | $6.02M | $4.91M |
| Cash at End | $23.79M | $60.9M | $91.49M | $42.76M | $64.13M | $24.21M | $6.02M |